Financial Counselors Inc. Has $969,000 Holdings in Zimmer Biomet Holdings, Inc. (ZBH)

Financial Counselors Inc. raised its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 33.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,278 shares of the medical equipment provider’s stock after buying an additional 2,063 shares during the period. Financial Counselors Inc.’s holdings in Zimmer Biomet were worth $969,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of ZBH. Strs Ohio boosted its position in Zimmer Biomet by 20.9% during the second quarter. Strs Ohio now owns 15,551 shares of the medical equipment provider’s stock valued at $1,996,000 after buying an additional 2,686 shares during the period. CIBC Asset Management Inc boosted its position in Zimmer Biomet by 0.5% during the second quarter. CIBC Asset Management Inc now owns 18,719 shares of the medical equipment provider’s stock valued at $2,404,000 after buying an additional 84 shares during the period. Bessemer Group Inc. boosted its position in Zimmer Biomet by 21.1% during the second quarter. Bessemer Group Inc. now owns 4,297 shares of the medical equipment provider’s stock valued at $552,000 after buying an additional 750 shares during the period. Daiwa Securities Group Inc. boosted its position in Zimmer Biomet by 9.7% during the second quarter. Daiwa Securities Group Inc. now owns 7,350 shares of the medical equipment provider’s stock valued at $944,000 after buying an additional 650 shares during the period. Finally, Sei Investments Co. boosted its position in Zimmer Biomet by 11.6% during the second quarter. Sei Investments Co. now owns 53,993 shares of the medical equipment provider’s stock valued at $6,932,000 after buying an additional 5,625 shares during the period. Institutional investors and hedge funds own 86.24% of the company’s stock.

Several analysts have issued reports on ZBH shares. Zacks Investment Research lowered shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 8th. Royal Bank Of Canada dropped their target price on shares of Zimmer Biomet to $125.00 and set an “outperform” rating for the company in a report on Tuesday, November 7th. Jefferies Group reiterated a “buy” rating and set a $136.00 target price on shares of Zimmer Biomet in a report on Friday, November 3rd. BMO Capital Markets dropped their target price on shares of Zimmer Biomet from $140.00 to $135.00 and set an “outperform” rating for the company in a report on Thursday, November 2nd. Finally, Edward Jones upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Thursday, November 9th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $133.71.

Zimmer Biomet Holdings, Inc. (ZBH) traded up $0.67 during mid-day trading on Wednesday, reaching $115.49. 1,261,000 shares of the company were exchanged, compared to its average volume of 1,358,476. Zimmer Biomet Holdings, Inc. has a 12 month low of $100.69 and a 12 month high of $133.49. The company has a market capitalization of $23,247.96, a P/E ratio of 14.23, a P/E/G ratio of 1.78 and a beta of 1.15. The company has a current ratio of 1.47, a quick ratio of 0.78 and a debt-to-equity ratio of 0.88.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The company had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.83 billion. During the same period in the previous year, the company earned $1.79 earnings per share. Zimmer Biomet’s quarterly revenue was down .8% on a year-over-year basis. equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.03 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Financial Counselors Inc. Has $969,000 Holdings in Zimmer Biomet Holdings, Inc. (ZBH)” was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://stocknewstimes.com/2017/12/06/financial-counselors-inc-has-969000-holdings-in-zimmer-biomet-holdings-inc-zbh.html.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply